A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/1992
11/10/1992	US5162303 Pharmaceutical compositions containing prolactin and methods for the use thereof
11/10/1992	US5162302 Thyroid Hormone, Growth Hormone Releasing Factor or Thyrotropin Releasing Hormone
11/10/1992	US5162217 Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
11/10/1992	US5162211 Process for producing a cyclic lipopeptide employing zalerion arboricola
11/10/1992	US5162114 Bone collagen matrix for xenogenic implants
11/10/1992	US5162111 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
11/10/1992	CA2102705A1 Wf11243 substance
11/10/1992	CA2086437A1 Phospholipid-targeted thrombolytic agents
11/10/1992	CA1309959C Parathryoid-specific radioimaging techniques
11/07/1992	WO1992019761A1 Assays for inhibitors of leukocyte adhesion
11/07/1992	WO1992019255A1 Gene manipulation and expression using genomic elements
11/07/1992	CA2109212A1 Assays for inhibitors of leukocyte adhesion
11/07/1992	CA2102628A1 Gene manipulation and expression using genomic elements
11/07/1992	CA2067973A1 Yeast-derived mitogen
11/05/1992	DE4214328A1 New phosphinate-contg. peptide derivs. - as collagenase inhibitors e.g. for treating gangrene or dental infections
11/04/1992	WO1992019259A1 Interleukin receptor targeted molecules for treatment of inflammatory arthritis
11/04/1992	EP0511943A2 Pyroglutamic acid derivatives as enhancers of learning processes and memory and pharmaceutical compositions comprising same
11/04/1992	EP0511940A2 Phosphono/biaryl substituted dipeptide derivatives
11/04/1992	EP0511917A1 Glycosylated prodrugs, process for their preparation and uses thereof
11/04/1992	EP0511866A2 Process for the crystallization of cyclic lipopeptides
11/04/1992	EP0511816A2 Neurotrophic peptide derivative
11/04/1992	EP0511747A1 Hybrid polypeptide containing an avidin binding polypeptide
11/04/1992	EP0511393A1 Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism
11/04/1992	EP0511347A1 Meta-substituted phenyl alanine derivatives
11/04/1992	EP0511306A1 Tumor killing effects of enterotoxins and related compounds
11/04/1992	EP0511302A1 Cytotoxic cell-specific protease-related molecules and methods
11/04/1992	EP0511300A1 Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
11/04/1992	EP0511285A1 Vector with multiple target response elements affecting gene expression
11/04/1992	EP0511234A1 Stable injectible solutions for factor viii.
11/04/1992	EP0317568B1 Use of granulocyte macrophage colony stimulating factor to prepare a medicament for treating bacterial infections
11/04/1992	EP0191814B1 Protein absorption enhancing agents
11/04/1992	CA2108886A1 Interleukin receptor targeted molecules for treatment of inflammatory arthritis
11/04/1992	CA2041828A1 Viscoelastic solution
11/03/1992	WO1992019229A1 Modified pollen grains for delivering biologically active substances to plants and animals
11/03/1992	US5160744 Verapmil therapy
11/03/1992	US5160483 Fragment of TNF-α for promoting wound healing
11/03/1992	CA2102211A1 Modified pollen grains for delivering biologically active substances to plants and animals
11/03/1992	CA2067598A1 Recombinant adn molecules coding for a receptor chain for the t-cell antigen, preparation process, antibody and drugs containing them
11/03/1992	CA1309805C Dipeptide derivative and synthesis and use thereof
11/03/1992	CA1309676C Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor viii:c
11/02/1992	WO1992019250A1 Method for treating hypothermia
11/02/1992	CA2102094A1 Method for treating hypothermia
11/02/1992	CA2067592A1 Phosphono/biaryl substituted dipeptide derviatives
11/02/1992	CA2067294A1 Process for crystalline cyclic lipopeptides
10/1992
10/29/1992	WO1992018630A1 Compound comprising a peptide sequence neutralizing the infection by human cytomegalovirus (hcmv) and composition containing such compound
10/29/1992	WO1992018629A1 Recombinant 3f8-type antibodies
10/29/1992	WO1992018627A1 Glial mitogenic factors, their preparation and use
10/29/1992	WO1992018626A1 WATER-SOLUBLE POLYPEPTIDES HAVING HIGH AFFINITY FOR INTERFERONS α AND $g(b)
10/29/1992	WO1992018610A2 Compositions and methods for endothelial binding
10/29/1992	WO1992018545A1 Novel heparin derivatives and process for the preparation thereof
10/29/1992	WO1992018538A1 A lymphocyte stimulating factor originating from the haemoflagellate trypanosoma
10/29/1992	WO1992018536A2 Method for detecting an localizing tissues having neurokinine 1 receptors
10/29/1992	WO1992018534A1 Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody
10/29/1992	WO1992018531A1 Growth hormone releasing factor analogs
10/29/1992	WO1992018530A1 SYNTHETIC CDw52(CAMPATH-1) PEPTIDE ANTIGEN
10/29/1992	WO1992018529A1 Increasing blood-brain barrier permeability with permeabilizer peptides
10/29/1992	WO1992018526A1 Production of phosphopeptides from casein
10/29/1992	WO1992018512A1 Aminoacyl derivatives of gem-diphosphonic acids, a process for the preparation thereof and pharmaceutical compositions containing them
10/29/1992	WO1992018490A1 Novel dna gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same
10/29/1992	WO1992018486A1 Improved process for the preparation of [1s-(1r, 2s, 3r*)]-n-(4-(morpholinylsulfonyl)-l-phenylalanyl-3-(2-amino-4-thiazolyl)-n-[(1-cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-l-alaninamide
10/29/1992	WO1992018160A2 Method for inhibiting adhesion of white blood cells to endothelial cells
10/29/1992	WO1992018159A1 Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
10/29/1992	WO1992018158A1 Method and composition for the treatment of herpes related disorders
10/29/1992	WO1992018157A1 Pharmaceutical packaging unit containing plasminogen activators for multiple-bolus administration
10/29/1992	WO1992018152A1 Use of müllerian inhibiting substance for treatment of certain tumors
10/29/1992	WO1992018149A1 Assay systems for neurotrophin activity
10/29/1992	WO1992018147A1 Convertible microemulsion formulations
10/29/1992	WO1992018145A1 Purification of müllerian inhibiting substance
10/29/1992	WO1992018142A1 Osteoinductive protein mixtures and purification processes
10/29/1992	WO1992018140A1 Activity-dependent neurotrophic factor
10/29/1992	WO1992018139A1 Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
10/29/1992	WO1992018138A1 Mammalian gap-43 compositions and methods of use
10/29/1992	WO1992018131A1 Method for potentiating primary drugs in treating multidrug resistant cells
10/29/1992	WO1992018112A1 Method of preventing nmda receptor complex-mediated neuronal damage
10/29/1992	WO1992018105A1 Improvements in pharmaceutical compositions
10/29/1992	WO1992018104A1 Pharmaceutical formulation and process
10/29/1992	WO1992016623A3 Receptors for bombesin-like peptides
10/29/1992	WO1992015607A3 Phenyl amidines derivatives useful as platelet aggregation inhibitors
10/29/1992	WO1992008985A3 Ligand-mediated immunofunctional hormone binding protein assay method
10/29/1992	DE4113385A1 Hybridtransposon mit pt-operon, plasmide und bakterienstaemme dafuer Hybrid transposon with pt-operon, plasmids and bakterienstaemme for it
10/29/1992	CA2585487A1 Water-soluble polypeptides with strong affinity for .alpha. and .beta. interferons
10/29/1992	CA2109100A1 Assay systems for neurotrophin activity
10/29/1992	CA2108786A1 Compositions and methods for endothelial binding
10/29/1992	CA2108566A1 Method for inhibiting adhesion of white blood cells to endothelial cells
10/29/1992	CA2108264A1 Use of mullerian inhibiting substance for treatment of certain tumors
10/29/1992	CA2106874A1 Method for detecting and localizing tissues having neurokinine 1 receptors
10/29/1992	CA2106673A1 Improved process for the preparation of [1s-(1r,2s,3r*)]-n-(4-morpholinylsulfonyl)-l-phenylalanyl-3-(2-amino-4-thiazolyl)-n-[(1-cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-l-alaninamide
10/29/1992	CA2084061A1 Growth hormone releasing factor analogs
10/28/1992	EP0511188A2 Novel binding peptides
10/28/1992	EP0511181A1 Saliva substitute
10/28/1992	EP0511003A1 Superactive GRF analogs
10/28/1992	EP0510949A2 Cytomodulating conjugates of members of specific binding pairs
10/28/1992	EP0510913A2 Pharmaceutical compositions comprising calcitonin
10/28/1992	EP0510912A1 Antimicrobial peptide and antimicrobial agent
10/28/1992	EP0510907A2 Bacteriophage lysins and their applications in destroying and testing for bacteria
10/28/1992	EP0510878A1 Human neurokinin-1 receptor
10/28/1992	EP0510731A1 LHRH Analog formulations
10/28/1992	EP0510691A1 DNA coding for human cell surface antigen
10/28/1992	EP0510662A1 bFGF mutein and its production
10/28/1992	EP0510356A1 Polyethylene glycol protein conjugates

1 ... 2957 2958 2959 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 ... 3163